Integra LifeSciences to Hold Second International Tissue Technologies Symposium on June 15 - 16, 2017 in Berlin, Germany

PLAINSBORO, N.J., June 15, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it is holding its second International Symposium on Tissue Technologies in Berlin, Germany on June 15 - 16, 2017.

Following the success of the first International Tissue Technologies Symposium in 2016, Integra is holding a second event, offering a two-day scientific symposium, which will bring together more than 100 surgeons from Europe and the United States. The 2017 International Symposium on Tissue Technologies will present an overview of different surgical techniques used in various medical fields, such as dermal reconstruction and regeneration, and plastic and reconstructive procedures in breast and complex abdominal wall repair. A faculty of world-renowned key opinion leaders will join the meeting to share their experience and viewpoints during the different scientific sessions and discussions.

"As a world leader in regenerative technologies, Integra is committed to offering a best-in-class medical education platform that will enable physicians to benefit from the experience of some of the world's leading plastic and reconstructive surgeons," said Stephane Corp, Integra's vice president, Tissue Technologies, Europe.

"We share with many surgeons a strong vision of all the scientific benefits brought by the soft tissue repair technologies. We believe that these technologies will continue to help improve patients' lives, and we are proud to offer a forum where practitioners can share best practices and techniques learned from their personal experience with patients."

About Integra
Integra LifeSciences is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care.  Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, and orthopedics and tissue technologies.  For more information, please visit www.integralife.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 2016. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

Contact Information:

Media:

Marie-Anne Girel (Europe)
[phone]
[e-mail]

Laurene Isip (U.S.)
+ 609 750 7984
[e-mail]

Investors:

Michael Beaulieu
+ 1 609 750 2827
[e-mail] 

---

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Integra LifeSciences Holdings Corp. via Globenewswire